Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans.

The history of pandemic influenza, along with the evolving epizootic of the highly pathogenic avian influenza A (H5N1) virus and the severity of associated human infections, serve as a warning to the world of the threat of another influenza pandemic. Conservative estimates suggest that up to 350 million people could die and many more would be affected, causing disruption to health-care systems, society, and the world's economy. WHO has encouraged countries to prepare in advance by developing influenza pandemic preparedness plans that involve public-health and pharmaceutical interventions. Vaccination is a cornerstone of these plans; however, a pandemic vaccine cannot be manufactured in advance because the next pandemic virus cannot be predicted. The concepts of vaccine stockpiling and prepandemic vaccination have thus become attractive. Human H5N1 vaccines are currently available and can induce heterotypic immunity. WHO and governments should give urgent consideration to the use of these vaccines for the priming of individuals or communities who would be at greatest risk of infection if an H5N1 influenza pandemic were to emerge.

[1]  R. Couch,et al.  Purified influenza A virus N2 neuraminidase vaccine is immunogenic and non-toxic in humans. , 1995, Vaccine.

[2]  L. Kurland,et al.  An epidemiologic and clinical evaluation of Guillain-Barré syndrome reported in association with the administration of swine influenza vaccines. , 1984, American journal of epidemiology.

[3]  Niall Johnson,et al.  Updating the Accounts: Global Mortality of the 1918-1920 "Spanish" Influenza Pandemic , 2002, Bulletin of the history of medicine.

[4]  A. Monto,et al.  Vaccines and Antiviral Drugs in Pandemic Preparedness , 2006, Emerging infectious diseases.

[5]  T. Hien,et al.  Avian influenza A (H5N1) , 2005, Journal of Clinical Virology.

[6]  B. Murphy,et al.  Live, Attenuated Influenza A H5N1 Candidate Vaccines Provide Broad Cross-Protection in Mice and Ferrets , 2006, PLoS medicine.

[7]  J. Taubenberger,et al.  The origin of the 1918 pandemic influenza virus: a continuing enigma. , 2003, The Journal of general virology.

[8]  A. Osterhaus,et al.  Cross-Protection against Lethal H5N1 Challenge in Ferrets with an Adjuvanted Pandemic Influenza Vaccine , 2008, PloS one.

[9]  K. Subbarao,et al.  Vaccines for Pandemic Influenza , 2006, Emerging infectious diseases.

[10]  B. Schwartz,et al.  Mass vaccination for annual and pandemic influenza. , 2006, Current topics in microbiology and immunology.

[11]  Y. Guan,et al.  H5N1 Outbreaks and Enzootic Influenza , 2006, Emerging infectious diseases.

[12]  D. Cummings,et al.  Strategies for mitigating an influenza pandemic , 2006, Nature.

[13]  A. Osterhaus,et al.  Pre- or post-pandemic influenza vaccine? , 2007, Vaccine.

[14]  Malbea A Lapete,et al.  Prevention and Control of Influenza Recommendations of the Advisory Committee on Immunization Practices ( ACIP ) , 2004 .

[15]  K. Nichol,et al.  Vaccines for seasonal and pandemic influenza. , 2006, The Journal of infectious diseases.

[16]  Mark A. Miller,et al.  The genesis and spread of reassortment human influenza A/H3N2 viruses conferring adamantane resistance. , 2007, Molecular biology and evolution.

[17]  A. Monto,et al.  Effect of neuraminidase antibody on Hong Kong influenza. , 1973, Lancet.

[18]  M. Zambon,et al.  Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial , 2006, The Lancet.

[19]  J. Taubenberger,et al.  1918 Influenza: the Mother of All Pandemics , 2006, Emerging infectious diseases.

[20]  G. Leroux-Roels,et al.  Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial , 2007, The Lancet.

[21]  R. Harpaz,et al.  Prevention of plague: recommendations of the Advisory Committee on Immunization Practices (ACIP). , 1996, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[22]  Samson S. Y. Wong,et al.  Avian Influenza Virus Infections in Humans , 2006, Chest.

[23]  M. Osterholm,et al.  Preparing for the next pandemic. , 2005, The New England journal of medicine.

[24]  C. Macken,et al.  Mitigation strategies for pandemic influenza in the United States. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Sandra Mounier-Jack,et al.  Pandemic influenza preparedness in the Asia–Pacific region , 2006, The Lancet.

[26]  B. Schwartz,et al.  Vaccination strategies for an influenza pandemic. , 2005, The Journal of infectious diseases.

[27]  Sabine Reiter,et al.  Prioritization strategies for pandemic influenza vaccine in 27 countries of the European Union and the Global Health Security Action Group: a review , 2007, BMC public health.

[28]  J. Treanor,et al.  Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans. , 2008, The Journal of infectious diseases.

[29]  S. Mounier-Jack,et al.  How prepared is Europe for pandemic infl uenza , 2006 .

[30]  A. Nizam,et al.  Containing Pandemic Influenza at the Source , 2005, Science.

[31]  K. Mozdzanowska,et al.  Prospects for Universal Influenza Virus Vaccine , 2006, Emerging infectious diseases.

[32]  A. Podda.  The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. , 2001, Vaccine.

[33]  R. Webster,et al.  Avian-to-human transmission of the PB1 gene of influenza A viruses in the 1957 and 1968 pandemics , 1989, Journal of virology.

[34]  E. Neumeier,et al.  Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines , 2002, Medical Microbiology and Immunology.

[35]  Glezen Wp.  Emerging Infections: Pandemic Influenza , 1996 .

[36]  R. Bugarini,et al.  Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. , 2005, The Journal of infectious diseases.

[37]  D. Fedson.  Preparing for Pandemic Vaccination: An International Policy Agenda for Vaccine Development , 2005, Journal of public health policy.

[38]  F. Hayden,et al.  Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial. , 2007, JAMA.

[39]  Larry R. Smith,et al.  Cross-Reactive Neuraminidase Antibodies Afford Partial Protection against H5N1 in Mice and Are Present in Unexposed Humans , 2007, PLoS medicine.

[40]  K. Stöhr,et al.  Will Vaccines Be Available for the Next Influenza Pandemic? , 2004, Science.

[41]  Gregory A Poland,et al.  Vaccines against avian influenza--a race against time. , 2006, The New England journal of medicine.

[42]  Keiji Fukuda,et al.  Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2002, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[43]  UK stocks up on antiviral drug to tackle flu outbreak , 2005, BMJ : British Medical Journal.

[44]  Maria Zambon,et al.  Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. , 2003, Vaccine.

[45]  D. Bernstein,et al.  Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. , 2008, The Journal of infectious diseases.

[46]  M. Thobaben,et al.  Prevention and Control of Influenza , 2003, MMWR. Morbidity and mortality weekly report.

[47]  Mark Wolff,et al.  Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. , 2006, The New England journal of medicine.

[48]  E. Montomoli,et al.  Pre-emptive vaccination against pandemic influenza virus. , 2007, Vaccine.

[49]  Ran D Balicer,et al.  Priority Setting for Pandemic Influenza: An Analysis of National Preparedness Plans , 2006, PLoS medicine.

[50]  H. Lawson,et al.  Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2007, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[51]  N. Grist.  Pandemic influenza 1918. , 1979, British medical journal.